AR and prostate cancer: The variant is not a significant eQTL for FOXP4 but the expression of the risk allele increases the expression of FOXP4. rs12769682, rs12769019 and rs4962419 are SNPs with PP of 0.27, 0.16 and 0.15, respectively, are eQTL for CTBP2. The previous study indicated that CTBP2 modulated the AR to promote prostate cancer progression41.